Efficacy and Safety of Topical Timolol for the Treatment of Facial Angiofibroma in Children with Tuberous Sclerosis Complex.

Autor:	Ghazavi M; Child Growth and Development Research Center, Isfahan University of Medical Sciences, Isfahan, Iran., Taheri S; Department of Pediatrics, Isfahan University of Medical Sciences, Isfahan, Iran., Sabzghabaee AM; Isfahan Clinical Toxicology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran., Tavakolifard N; Department of Community and Family Medicine, Isfahan University of Medical Sciences, Isfahan, Iran., Yaghini O; Child Growth and Development Research Center, Isfahan University of Medical Sciences, Isfahan, Iran., Faghihi G; Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran., Afshar K; Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran., Abtahi-Naeini B; Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.; Pediatric Dermatology Division of Department of Pediatrics, Isfahan University of Medical Sciences, Isfahan, Iran.
Jazyk:	angličtina
Zdroj:	Journal of research in pharmacy practice [J Res Pharm Pract] 2023 Aug 29; Vol. 11 (4), pp. 144-150. Date of Electronic Publication: 2023 Aug 29 (Print Publication: 2022).
DOI:	10.4103/jrpp.jrpp_30_23
Abstrakt:	Objective: This study aimed to assess the efficacy and safety of topical timolol in treating facial angiofibromas (FAs) in pediatric patients with tuberous sclerosis complex (TSC). Methods: A prospective clinical trial was conducted involving 15 children diagnosed with TSC and presenting with FAs. The participants were administered topical timolol gel 0.5% twice daily. Prior to the intervention, the severity of FAs in each patient was evaluated using the FA severity index (FASI), which assessed erythema, size, and extent of lesions. Clinical response was assessed at weeks 2 and 4 during the intervention period as well as 1 month after discontinuation of treatment. Findings: Four weeks after discontinuing topical timolol 0.5%, statistically significant reductions were observed in the mean FASI score, erythema, size, and extent of lesions ( P < 0.0001, P < 0.0001, P = 0.012, P = 0.008, respectively). FASI scores at 4 and 12 weeks postintervention, as well as 4 weeks after treatment cessation, demonstrated a significant decrease compared to baseline ( P < 0.001). Erythema and extension scores also exhibited a significant decrease 1 month after treatment cessation compared to baseline ( P < 0.05), while the mean size of lesions before and after the intervention did not show a statistically significant difference ( P = 0.004). Conclusion: Topical timolol 0.5% represents a cost-effective and readily available treatment option for pediatric patients with FAs associated with tuberous sclerosis. Competing Interests: There are no conflicts of interest. (Copyright: © 2023 Journal of Research in Pharmacy Practice.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu